Biological Intellectual Property Protection Act of 2025
- Bill Number
- S. 3452
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 1
- Policy Area
- International Affairs
- Status
- Introduced
- Latest Action
- 2025-12-11: Read twice and referred to the Committee on Banking, Housing, and Urban Affairs.
- Last Updated
- 2026-01-15T07:05:15Z
AI-Generated Summary
Purpose
The Biological Intellectual Property Protection Act of 2025 aims to safeguard U.S. national security by restricting the export of sensitive intellectual property and information related to synthetic biology—specifically digital sequences of synthetic DNA or RNA—to foreign entities of concern. It addresses perceived threats from adversaries, such as the People's Republic of China, which could use this technology for military modernization, intelligence, or human rights abuses.
Key Provisions
- Sense of Congress: Declares that China is exploiting U.S. data and intellectual property through a "military-civil fusion" strategy, where civilian entities support military goals. It highlights Chinese laws (e.g., National Security Law of 2015, National Intelligence Law of 2017) that mandate citizen cooperation with security priorities, and warns that exporting synthetic DNA/RNA sequences risks intellectual property theft.
- License Requirement: Amends the Export Control Reform Act of 2018 to require a license from the Secretary (likely of Commerce) for the export, reexport, or in-country transfer of human- or AI-designed digital sequences of synthetic DNA or RNA to a "foreign entity of concern." This takes effect one year after enactment.
- Exception: Licenses are not needed for certain publicly available or fundamental research information, as defined in the Export Administration Regulations (a set of rules governing exports).
- Definitions:
- Digital sequence: A digital file representing the identity, order, and modifications of DNA or RNA molecules.
- Foreign country of concern: Refers to nations like China, as defined in existing law (e.g., those posing risks to U.S. technology security).
- Foreign entity of concern: Includes government entities, persons under the jurisdiction of a foreign country of concern, or entities owned/controlled by them.
- Synthetic DNA or RNA: Artificially constructed or chemically synthesized nucleic acid molecules (building blocks of genetic material) that can replicate in cells or pair with natural ones.
Significant Changes to Existing Law
- Inserts a new section (1758A) into the Export Control Reform Act of 2018, expanding export controls to specifically target synthetic biology technologies.
- Introduces targeted licensing for digital genetic sequences, building on but narrowing focus to human/AI-designed synthetic DNA/RNA, rather than all biological materials.
- Aligns with broader U.S. export rules but adds biotech-specific protections not previously detailed in this way.
Potential Impacts
- Government Agencies: The Department of Commerce (via its Bureau of Industry and Security) will handle licensing reviews, increasing administrative workload and enforcement needs to monitor biotech exports.
- Citizens and Businesses: U.S. biotech companies, researchers, and gene synthesis firms may face delays or restrictions in international collaborations, potentially slowing innovation or raising costs, but enhancing IP protection.
- International Relations: Could heighten tensions with countries like China by limiting technology access, signaling U.S. commitment to curbing dual-use (civilian-military) tech transfers, and possibly prompting retaliatory export controls from affected nations.
Main Stakeholders Affected
- U.S. Biotech Industry: Companies and researchers involved in synthetic biology, who must comply with new licensing for exports.
- Foreign Entities: Particularly in China, including government-linked firms and researchers, facing barriers to U.S. genetic sequences.
- U.S. Government: Agencies like Commerce and national security bodies, responsible for implementation and oversight.
- Academic and Research Institutions: U.S. and international entities engaged in genetic engineering, potentially impacted by export limits on collaborative work.
Notable Legal, Constitutional, or Political Implications
- Legal: Strengthens export control frameworks under existing statutes, ensuring compliance with international trade laws while carving out exceptions for basic research to avoid overreach. May lead to legal challenges if licensing is seen as overly burdensome on free trade or speech in scientific exchange.
- Constitutional: Balances national security (a core federal power) with First Amendment concerns over restricting scientific information, though exceptions for public data mitigate this.
- Political: Reflects bipartisan concern over China as a strategic rival, advancing U.S. policy on technology protection amid global biotech competition. Could influence future legislation on emerging technologies like AI-driven biology.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (2)
Sen. Hassan, Margaret Wood [D-NH], Sen. Budd, Ted [R-NC]
Recent Actions
- 2025-12-11: Read twice and referred to the Committee on Banking, Housing, and Urban Affairs.
- 2025-12-11: Introduced in Senate
Bill Versions
- Biological Intellectual Property Protection Act of 2025 — issued 2025-12-11 — PDF (6 pages)